Minerva Neurosciences (NASDAQ:NERV) Shares Cross Below Two Hundred Day Moving Average – What’s Next?

Minerva Neurosciences, Inc (NASDAQ:NERV)’s stock price passed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $5.19 and traded as low as $4.70. Minerva Neurosciences shares last traded at $4.74, with a volume of 122,326 shares trading hands.

Minerva Neurosciences News Summary

Here are the key news stories impacting Minerva Neurosciences this week:

• Positive Sentiment: Zacks upgraded Minerva Neurosciences (NERV) to a Buy rank, signaling growing optimism about the company’s earnings outlook. Article Title
• Positive Sentiment: HC Wainwright raised multiple forward EPS estimates for NERV, including FY2026, FY2027, and several quarterly periods, suggesting analysts see a much better earnings trajectory ahead. Article Title
• Positive Sentiment: Technical commentary suggests the recent selloff may be overextended, with Minerva Neurosciences now in oversold territory and potentially due for a trend reversal. Article Title
• Neutral Sentiment: HC Wainwright kept a Neutral rating and a $7.00 price target on NERV, so the latest estimate changes are supportive but not a full bullish call. Article Title
• Negative Sentiment: The stock had already fallen sharply over the past month and recently slipped below its 200-day moving average, showing that longer-term momentum remains weak. Article Title

Wall Street Analyst Weigh In

NERV has been the subject of several recent analyst reports. Wall Street Zen cut Minerva Neurosciences from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. HC Wainwright reaffirmed a “neutral” rating and issued a $7.00 price target (up from $4.00) on shares of Minerva Neurosciences in a research note on Thursday, March 12th. Citizens Jmp started coverage on shares of Minerva Neurosciences in a research note on Wednesday, April 15th. They issued a “market outperform” rating and a $14.00 price target for the company. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Minerva Neurosciences in a research report on Friday, March 27th. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Minerva Neurosciences has a consensus rating of “Hold” and an average target price of $10.50.

Minerva Neurosciences Stock Performance

The firm has a 50 day simple moving average of $6.27 and a two-hundred day simple moving average of $5.20. The firm has a market capitalization of $234.35 million, a P/E ratio of -0.17 and a beta of -0.08.

Minerva Neurosciences (NASDAQ:NERV) last posted its earnings results on Tuesday, May 5th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.04). Sell-side analysts anticipate that Minerva Neurosciences, Inc will post -0.2 earnings per share for the current year.

Institutional Investors Weigh In On Minerva Neurosciences

A number of hedge funds have recently made changes to their positions in the business. Bank of America Corp DE raised its stake in shares of Minerva Neurosciences by 78,272.5% during the 1st quarter. Bank of America Corp DE now owns 39,970 shares of the biopharmaceutical company’s stock worth $241,000 after purchasing an additional 39,919 shares during the period. Janus Henderson Group PLC raised its holdings in shares of Minerva Neurosciences by 47,614.0% in the 1st quarter. Janus Henderson Group PLC now owns 4,294,259 shares of the biopharmaceutical company’s stock worth $25,873,000 after purchasing an additional 4,285,259 shares during the period. OMERS ADMINISTRATION Corp bought a new stake in shares of Minerva Neurosciences in the 1st quarter worth approximately $62,000. Cannon Global Investment Management LLC bought a new stake in shares of Minerva Neurosciences in the 1st quarter worth approximately $107,000. Finally, Millennium Management LLC bought a new stake in shares of Minerva Neurosciences in the 4th quarter worth approximately $554,000. 34.56% of the stock is currently owned by institutional investors.

About Minerva Neurosciences

Minerva Neurosciences, Inc is a clinical?stage biopharmaceutical company focused on developing novel therapies for central nervous system (CNS) disorders. The company’s research and development efforts are directed toward addressing unmet needs in psychiatric and neurological conditions, leveraging its expertise in neuropharmacology and receptor modulation. Minerva’s goal is to bring forward differentiated molecules that can offer improved efficacy and safety profiles compared to existing treatments.

The company’s most advanced programs include roluperidone (formerly MIN-101), which has been investigated for the treatment of negative symptoms of schizophrenia, and MIN-117, a novel serotonergic agent being evaluated in major depressive disorder.